Sierra Oncology (SRRA) Trading Down 9.4%

Shares of Sierra Oncology Inc (NASDAQ:SRRA) were down 9.4% on Monday . The company traded as low as $3.20 and last traded at $3.26. Approximately 1,168,474 shares were traded during mid-day trading, an increase of 97% from the average daily volume of 594,347 shares. The stock had previously closed at $3.60.

A number of analysts recently weighed in on SRRA shares. Zacks Investment Research lowered shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Jefferies Group raised shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.00.

The firm has a market capitalization of $169.44 and a P/E ratio of -3.41.

Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.03. equities research analysts predict that Sierra Oncology Inc will post -0.85 EPS for the current fiscal year.

WARNING: “Sierra Oncology (SRRA) Trading Down 9.4%” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/10/sierra-oncology-srra-trading-down-9-4.html.

About Sierra Oncology

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply